速溶錠の市場規模・シェア・成長分析 (薬剤クラス別、適応症別、流通チャネル別、地域別)：産業予測 (2025～2032年)

世界の速溶錠の市場規模は2023年に56億米ドルと評価され、2024年の61億米ドルから2032年には120億6,000万米ドルに成長し、予測期間 (2025-2032年) のCAGRは8.9%で成長する見通しです。

速溶錠 (ファストメルト錠剤) 市場は、水や咀嚼を必要とせずに溶ける固形の経口剤形に対する需要の増加により成長を遂げています。この革新的なソリューションは、活動的な人々、高齢者、嚥下困難な人々に対応し、さまざまな場面で薬物へのアクセス性を確保します。最近の経口溶解ドラッグデリバリーシステムの進歩により、薬物療法への迅速な介入、バイオアベイラビリティの改善、安定性の向上などの機能が強化されています。ユーザーフレンドリーな製造プロセスと安定した投与により、乗り物酔い、アレルギー発作、急性の咳など、迅速な作用発現が不可欠な症状への対応に理想的です。その結果、速溶錠は、効果的で便利な薬物療法を求める多様な人々にとって不可欠な選択肢となりつつあります。

目次

イントロダクション

• 分析目的
• 市場範囲
• 定義

分析手法

• 情報調達
• 二次・一次データの手法
• 市場規模予測
• 市場の想定と制約

エグゼクティブサマリー

• 市場の概要と展望
• 需給動向の分析
• セグメント別の機会分析

市場力学と展望

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーター分析

市場の主な考察

• 主な成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場魅力度指数 (2024年)
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 技術分析
• 規制分析
• 特許分析
• ケーススタディ

世界の速溶錠の市場規模・CAGR：薬剤クラス別 (2025～2032年)

• 市場概要
• 抗精神病薬
• 抗てんかん薬
• 中枢神経刺激薬
• 抗不安薬
• 抗パーキンソン病薬
• 降圧剤
• 非ステロイド性抗炎症薬
• 抗アレルギー薬
• プロトンポンプ阻害剤
• その他

世界の速溶錠の市場規模・CAGR：適応症別 (2025～2032年)

• 市場概要
• 中枢神経疾患
• 消化器疾患
• 中枢神経系 (CVS) 障害
• アレルギー
• その他

世界の速溶錠の市場規模・CAGR：流通チャネル別 (2025～2032年)

• 市場概要
• 病院薬局
• 小売薬局
• ドラッグストア
• オンライン薬局

世界の速溶錠の市場規模・CAGR (2025～2032年)

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング (2024年)
• 主要企業が採用した戦略
• 市場の近年の動向
• 主要企業の市場シェア (2024年)
• 主要企業のプロファイル
  • 企業概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較 (2022～2024年)

主要企業のプロファイル

• Teva Pharmaceutical Industries Ltd. (イスラエル)
• Novartis AG (スイス)
• AstraZeneca (英国)
• Mylan N.V. (米国)
• Pfizer Inc. (米国)
• Johnson & Johnson Services Inc. (米国)
• F. Hoffmann-La Roche Ltd. (スイス)
• Merck & Co., Inc. (米国)
• Bausch Health (カナダ)
• GlaxoSmithKline plc (英国)
• Sun Pharmaceutical Industries Ltd. (インド)
• Bayer AG (ドイツ)
• Eli Lilly and Company (米国)
• Dr. Reddy's Laboratories Ltd. (インド)
• Takeda Pharmaceutical Company Limited (日本)
• Kissei Pharmaceutical Co., Ltd. (日本)
• Zydus Lifesciences Ltd. (インド)
• Torrent Pharmaceuticals Ltd. (インド)
• Cipla Ltd. (インド)
• Aurobindo Pharma Ltd. (インド)

結論と推奨事項

Global Fast Melt Tablets Market size was valued at USD 5.6 billion in 2023 and is poised to grow from USD 6.1 billion in 2024 to USD 12.06 billion by 2032, growing at a CAGR of 8.9% during the forecast period (2025-2032).

The fast-melting tablet market is experiencing growth due to the increasing demand for solid oral dosage forms that dissolve without the need for water or chewing. This innovative solution caters to active individuals, the elderly, and those with swallowing difficulties, ensuring drug accessibility in various scenarios. Recent advancements in oral-dissolving drug delivery systems have enhanced their capabilities, offering rapid intervention for drug therapy, improved bioavailability, and enhanced stability. Their user-friendly manufacturing process and consistent dosing make them ideal for handling conditions such as motion sickness, allergic attacks, or acute coughing, where a quick onset of action is essential. As a result, fast-dissolving tablets are becoming an essential option for diverse demographics seeking effective and convenient medication solutions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Fast Melt Tablets market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Fast Melt Tablets Market Segmental Analysis

Global Fast Melt Tablets Market is segmented by Drug Class, Indication, Distribution channel and region. Based on Drug Class, the market is segmented into Anti-Psychotics, Anti-Epileptics, CNS Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensive, NSAIDS, Anti-Allergy Drugs, Proton Pump Inhibitors and Others. Based on Indication, the market is segmented into CNS Diseases, GI Diseases, CVS Disorders, Allergy and Others. Based on Distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Fast Melt Tablets Market

The growth of the Global Fast Melt Tablets market is significantly influenced by several factors. Chief among these is the increasing aging population, many of whom struggle with swallowing traditional pills. The heightened focus on product promotion aimed at improving consumer awareness and patient care is also contributing to market dynamics. As patients seek cost-effective solutions that enhance their quality of life, the demand for fast melt tablets continues to rise. Furthermore, the risks associated with choking or asphyxiation from conventional oral solid formulations underscore the necessity for alternatives. Technological advancements have enabled the development of fast melt tablets that dissolve swiftly, often within three minutes, thereby aligning with pharmacopoeia standards and further driving market growth.

Restraints in the Global Fast Melt Tablets Market

One significant constraint impacting the global fast melt tablets market is the difficulty associated with handling these products. Due to their porous and delicately formed structure, fast melt tablets lack robustness and are often created with minimal compression, rendering them fragile and prone to breakage. This vulnerability complicates storage, transportation, and dispensing processes, ultimately hindering market expansion. As a result, manufacturers face challenges in ensuring product integrity, which could lead to increased costs and limitations in distribution. Addressing these handling concerns is essential for overcoming barriers to growth within the fast melt tablets sector.

Market Trends of the Global Fast Melt Tablets Market

The Global Fast Melt Tablets market is experiencing robust growth, primarily fueled by the increasing demand from the geriatric population, who favor these formulations for their convenience and rapid action. Fast melt tablets eliminate first-pass metabolism issues associated with traditional oral medications, enhancing bioavailability and patient adherence. As this demographic seeks efficient self-administration options with fewer side effects, the trend towards fast-dissolving doses is gaining momentum. While technical challenges in formulation exist, ongoing research and development efforts are anticipated to address these hurdles, presenting significant opportunities for market expansion in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Regulatory Analysis
• Patent Analysis
• Case Studies

Global Fast Melt Tablets Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Anti-Psychotics
• Anti-Epileptics
• CNS Stimulants
• Anxiolytics
• Anti-Parkinsonian Drugs
• Anti-Hypertensive
• NSAIDS
• Anti-Allergy Drugs
• Proton Pump Inhibitors
• Others

Global Fast Melt Tablets Market Size by Indication & CAGR (2025-2032)

• Market Overview
• CNS Diseases
• GI Diseases
• CVS Disorders
• Allergy
• Others

Global Fast Melt Tablets Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

Global Fast Melt Tablets Market Size & CAGR (2025-2032)

• North America (Drug Class, Indication, Distribution channel)
  • US
  • Canada
• Europe (Drug Class, Indication, Distribution channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Indication, Distribution channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Indication, Distribution channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Indication, Distribution channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kissei Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations